Drug resistance has become one of the biggest challenges in drug discovery and/or development and has attracted great research interests worldwide. During the past decade, computational strategies have been developed to predict target mutation-induced drug resistance. Meanwhile, various molecular design strategies, including targeting protein backbone, targeting highly conserved residues and dual/multiple targeting, have been used to design novel inhibitors for combating the drug resistance. In this article we review recent advances in development of computational methods for target mutation-induced drug resistance prediction and strategies for rational design of novel inhibitors that could be effective against the possible drug-resistant mutants of the target.
Introduction
With the development of computer science and structure biology, structure-based drug design has become one of routine approaches of drug discovery today. Aided by structure-based design, many pharmacologists usually focus on improving the potency of drug candidates from micromolar to nanomolar and even picomolar level. However, the stronger the selection pressure, the more rapidly resistance develops because drug target has been proved to be plastic [1] . Take HIV-1 virus as an example, it has been estimated that there are 10 4 -10 5 mutations every day for each single residue in an untreated HIV-1 infected individual [2] . Hence, it is an interesting task and urgent demand to develop new strategies to combat drug resistance. Generally speaking, drug resistance can be divided into several categories ( Fig. 1) [3], such as target mutation, epigenetic modifications represented by gene expression variations of the target protein [4] and drug bypass signaling [5, 6] . It is desirable to account for the possible drug resistance in the course of drug discovery to overcome the drug resistance as much as possible. Thus, it is interesting to computationally predict the possible target mutation-induced drug resistance and design possible inhibitors that are also effective against the resistant variants (RVs) inhibitors. In this review we focus on recent advances of structure-based approaches to drug resistance prediction and molecular design strategies to combat target mutation-induced resistance.
Structure-based prediction of mutation-induced drug resistance
The fast and precise prediction of drug resistance mutations could help to avoid therapy failure and/or facilitate therapy redesign after failure. Hence, various computational methods have been used to carry out mutation-induced drug resistance prediction based on the known RV of the target. Commonly, the side chains of amino acids in the target protein structure are replaced by the corresponding ones in a mutant during the computational modeling which aims to model the mutant structure. Molecular docking [7, 8] , molecular dynamics (MD) simulation [9] [10] [11] [12] [13] and computational mutation scanning (CMS) [14, 15] methods have been used to determine the binding structures of a drug in various mutants.
Because of the high efficiency of the computation, molecular docking is a good choice for the resistance prediction of a large number of mutants or compounds. For a potential problem, the simple docking cannot deal with the highly flexible proteininhibitor complex structures very well. MD simulation has an advantage in conformational flexibility sampling and researchers can peer into the motion at atom level from the obtained MD trajectories. On the down side, the MD method is relatively more time-consuming and might not be suitable for simulating a large number of mutants.
To predict mutation-induced shift of the binding free energy for a given mutant, Hao et al. [15] developed a novel drug resistance prediction method -CMS, which is a reasonable combination of the MD simulation on wild-type (WT) protein target and subsequent mutational scanning (one-step perturbation) for a larger number of mutants. For the possible limitation of the methodology, the CMS method can be accurate only under a presumption 
FIGURE 1
Drug resistance mechanisms. Drug resistance can be divided into two main categories: target mutation and non-target mutation. Target mutation affects the binding of the inhibitor (1). Non-target mutations include epigenetic modifications (2) and drug bypass signaling (3). Epigenetic modifications can be grouped into DNA methylation, histone modifications and nucleosome positioning. A representative is gene expression variations of the target protein (2) . Resistance can also occur on drug bypass signaling pathway, which results in less drug accumulation by increasing drug elimination or metabolizing (3). [51] that the mutation does not considerably change the binding mode of the drug. In other words, the CMS calculation could significantly overestimate the drug resistance associated with the mutant when the mutation actually causes a considerable change in the binding mode. Based on the CMS calculations, the mutationinduced drug resistance mechanisms include the following categories: (i) decrease in the enthalpy contribution to the binding affinity, (ii) decrease in the entropic contribution to the binding affinity, (iii) decrease in both the enthalpy and entropic contributions, (iv) no significant change in the enthalpy and entropic contribution, (v) decrease in the enthalpy contribution compensated with increase in the entropic contribution and (vi) decrease in the entropic contribution compensated with increase in the enthalpy contribution. Statistical learning methods [16] have also been used for sequence-based drug resistance predictions. By using these purely empirical approaches, one only needs to know the primary structure (sequence) of the target protein, but a large number of known resistance and non-resistance mutants are required for the model training. Well-trained models could have satisfactory predictive ability which is measured by the prediction accuracy of the resistance level (Table 1) .
Furthermore, there have been efforts to develop other effective computational approaches to the drug resistance prediction based on a combined use of structure-and sequence-based methods [17] . In particular, Zhang et al. [18] proposed a unique procedure that combines Bayesian statistical modeling with MD simulations to investigate complex interactions of drug resistance mutations of the HIV-1 protease and reverse transcriptase. They presented a statistical procedure that first detects mutation combinations associated with drug resistance and then the molecular basis of their statistical predictions was further studied by carrying out MD simulations and free energy calculations to infer detailed interaction structures of these mutations. Their proof-of-concept study has demonstrated that the insights obtained from the MD simulations guided by the Bayesian inference can shed light on how to improve the potency of drugs to combat the resistance. Table 1 summarizes the results associated with different methods reported in recent years. Predictive ability of these studies is mainly evaluated by qualitative or quantitative indicators. Qualitatively, drug resistance can be divided into different levels, in which prediction accuracy is in the range of 82-96% for structurebased methods, 80-95% for sequence-based methods and 65-80% a Various criteria used to represent the prediction accuracy in the references cited:Criterion 1: Percentage of the correctly predicted resistance and non-resistance mutations.Criterion 2:
Percentage of the correctly predicted drug resistance levels (high, middle, low and no resistance) in which the low resistance level means less than tenfold resistance (in terms of the IC 50 value increase), the middle resistance level means less than 100-fold but higher than tenfold resistance and the high resistance level means higher than 100-fold resistance. 
Structure-based design of RV inhibitors
It is interesting to design and develop more effective drugs that can be active for both the WT protein target and its possible variants. Detailed analysis on a wide range of X-ray crystal structures of protein-drug complexes, along with biological data on drug-resistant mutations, has identified structural factors important for rational design of new inhibitors whose binding affinity with the target is not (or less) affected by the target mutations.
Targeting protein backbone
Amino acid mutations change the side chains of mutated residues, but do not change the backbone. Inhibitors designed to have strong hydrogen-bond interactions with the backbone atoms of the target protein can probably reserve important interactions with the mutants and, thus, effectively combat drug resistance (Figs 2a and 3a ) [19] [20] [21] [22] . For example, a series of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thymine (HEPT) analogs were computationally designed and synthesized [23] to form two hydrogen bonds with the backbone carbonyl group of Lys101 of HIV-1 reverse transcriptase. Most of these compounds are highly potent inhibitors of WT HIV-1 reverse transcriptase and its resistant mutants.
It is well known that darunavir displayed ultrahigh HIV protease inhibitor potency (K i = 16 pM) and retained the potency against many highly drug-resistant HIV mutants by forming hydrogen bonds between bis-tetrahydrofuran (bis-THF) moiety and the backbone NH groups of Asp29 and Asp30 [24] . Ghosh et al. [25] further predicted that the incorporation of another tetrahydrofuran ring on the bis-THF ligand could provide additional favorable binding with the backbone atoms. The prediction guided them to design and synthesize a series of novel oxatricyclic ligands that 'displayed potent activity against a variety of multidrug-resistant clinical HIV-1 strains, with EC 50 values ranging from 0.6 to 4.3 nm, a nearly tenfold improvement over darunavir' [25] . 
FIGURE 3
Chemical structures of known representative inhibitors (designed by using different strategies) that are potent toward WT and many drug-resistant mutants.
Targeting highly conserved residues
The analysis of the reported resistant mutants demonstrated that few drug-resistant mutations happened on highly conserved residues [26] . Hence, another widely accepted strategy is to design inhibitors that have significant interactions with only the highly conserved residues so as to minimize the dependence of the activity on the non-conserved residues (Figs 2b and 3b) [27] [28] [29] [30] .
b-Lactam antibiotics have long been used for the treatment of bacterial infections because they bind irreversibly to penicillinbinding proteins (PBPs) that are vital for the cell wall biosynthesis. Many pathogens express drug-insensitive PBPs to render b-lactams ineffective, which reveals a need for new types of PBP inhibitors that are active against the resistant mutants. Contreras-Martel et al. [31] identified boronic acid inhibitors that are active against clinically relevant pathogens and may overcome b-lactam resistance by mimicking the tetrahedral catalytic intermediate.
In addition, Schiffer et al. developed a 'substrate envelope' hypothesis that inhibitors located within the overlapping consensus volume of the substrates were less likely to be susceptible to drug-resistant mutations than inhibitors that protrude beyond this envelope [32] . As mutations impacting such inhibitors would simultaneously impact the process of substrate perception [33] [34] [35] [36] [37] . For an ideal inhibitor located within the substrate envelope, there will be no chance for drug resistance mutation except for the rare coevolution of the protein and substrate [38] . To evaluate this hypothesis, more than 130 new inhibitors of HIV-1 protease were designed and synthesized with and without the substrate-envelope constraints [37] . In general, inhibitors that fit within the substrate envelope have flatter profiles with respect to drug-resistant protease variants than inhibitors that protrude beyond the substrate envelope. Thus, the acquired results from testing this hypothesis are encouraging as they have demonstrated that combining the substrate-envelope hypothesis with structure-based drug design may result in new inhibitors that are less susceptible to drug-resistant mutations.
Dual/multiple targeting
It has been well known that drug combination (combination therapy) is an effective strategy to overcome drug resistance. To improve patient compliance, two or more drugs can also be coformulated into a single tablet. On the down side, complex pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles and unpredictable drug-drug interaction could have a significant impact on the risks and costs of developing multicomponent drugs [39] . Dual/multiple targeting strategy, which uses a single molecular entity to inhibit multiple protein targets, could significantly reduce the likelihood of drug resistance without the extra patient compliance problem (Figs 2c and 3c) . For a particular example, ABCB1 (ATP-binding cassette, sub-family B, MDR1) overexpression protects leukemia cells from drug-induced apoptosis and decreases sensitivity of leukemia cells to cytotoxic chemotherapeutic agents. Mutations in ABCB1 are one of the mechanisms for chemoresistance common to a wide spectrum of cancers. Recent studies showed that myeloid cell leukemia sequence 1 (BCL2-related) gene (MCL1) was upregulated in numerous hematological and solid tumor malignancies. Ji et al. demonstrated that MCL1 mediated drug resistance through a different mechanism and the depletion of both MCL1 and ABCB1 showed an additive effect in reversing drug resistance and promoting drug-induced apoptosis [40] . So, simultaneous targeting of MCL1 and ABCB1 could be an effective approach to overcome drug resistance in leukemia. However, a key challenge of dual/multiple targeting is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable PK profile.
Concluding remarks
Recent studies have revealed that the efficacy of many small molecule drugs can be hampered by the rapid emergence of drug resistance mutations on the target proteins and that the battle against mutation-induced drug resistance has become increasingly intense [41, 42] . Rational strategies to combat mutation-induced drug resistance should be accounted for in the course of drug discovery and/or development to prevent the emergence of resistance as much as possible.
The structure-based methods are particularly useful for computational prediction of resistant mutants and RV inhibitor design. The primary challenge of structure-based drug resistance prediction is how to appropriately balance the prediction accuracy and computational efficiency. It would be an ideal approach to efficiently predict the drug resistance level and understand the resistance mechanism associated with each resistant mutant through an appropriately combined use of structure-based methods and statistical learning methods. Besides, targeting protein backbone, targeting highly conserved residues, and dual/multiple targeting have been recognized as effective strategies for rational design of novel inhibitors with reduced resistance risk. Structure-based drug design could eventually lead to the discovery and development of novel, more potent and safer drugs with potentially different resistance profiles compared to the existing drugs. It would be interesting to further develop and validate novel strategies and/or make an appropriately combined use of available strategies. One can reasonably expect that the use of structure-based methods will become more and more popular in the battle against drug resistance.
